



OPEN ACCESS

EDITED AND REVIEWED BY

Zhaohui Wang,
Chinese Academy of Medical Sciences
and Peking Union Medical College, China

*CORRESPONDENCE

Jiandong Jiang,
✉ jiang.jdong@163.com
Xiao Ding,
✉ dingxiao@mail.kib.ac.cn
Lulu Wang,
✉ wanglulu@imb.cams.cn

RECEIVED 03 August 2023

ACCEPTED 14 August 2023

PUBLISHED 28 August 2023

CITATION

Guo X, Li R, Cui J, Hu C, Yu H, Ren L,
Cheng Y, Jiang J, Ding X and Wang L
(2023), Corrigendum: Induction of RIPK3/
MLKL-mediated necroptosis by *Erigeron
breviscapus* injection exhibits potent
antitumor effect.

Front. Pharmacol. 14:1271953.

doi: 10.3389/fphar.2023.1271953

COPYRIGHT

© 2023 Guo, Li, Cui, Hu, Yu, Ren, Cheng,
Jiang, Ding and Wang. This is an open-
access article distributed under the terms
of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Induction of RIPK3/ MLKL-mediated necroptosis by *Erigeron breviscapus* injection exhibits potent antitumor effect

Xiuping Guo¹, Rui Li¹, Jinjin Cui¹, Chujuan Hu¹, Haoyang Yu¹,
Ling Ren¹, Yangyang Cheng¹, Jiandong Jiang^{1*}, Xiao Ding^{2*} and
Lulu Wang^{1*}

¹Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, ²State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China

KEYWORDS

Erigeron breviscapus injection, Dengzhanxixin, *Erigeron breviscapus* (Vant.) Hand.-Mazz, colorectal cancer, necroptosis, drug resistance

A Corrigendum on

Induction of RIPK3/MLKL-mediated necroptosis by *Erigeron breviscapus* injection exhibits potent antitumor effect

by Guo X, Li R, Cui J, Hu C, Yu H, Ren L, Cheng Y, Jiang J, Ding X and Wang L (2023). *Front. Pharmacol.* 14:1219362. doi: 10.3389/fphar.2023.1219362

In the published article, there was an error in [Figure 2](#) as published. The upper panels in [Figures 2B, D](#) were inadvertently misused during the final assembly of [Figure 2](#). The corrected [Figure 2](#) appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2 EBI suppresses growth, migration, and invasion of SW620 cells. **(A)** SW620 cells were observed for morphologic changes at 12 h after EBI (10, 15, 20, 40, and 100 µg/mL) treatment. Scale bars indicate 50 µm. **(B, C)** The representative image **(B)** and quantitative analysis **(C)** of migrated cells after exposure to EBI (10, 15, 20, and 40 µg/mL, 24 h). Scale bars indicate 50 µm. **(D, E)** The representative image **(D)** and quantitative analysis **(E)** of invaded cells after exposure to EBI (10, 15, 20, and 40 µg/mL, 24 h). Scale bars indicate 50 µm. Mean ± SEM. ***p < 0.001, ****p < 0.0001 vs. EBI 0 µg/mL group (one-way ANOVA).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.